血管内皮生长因子多态性对糖尿病患者外周动脉疾病严重程度的影响。

Impact of VEGF polymorphisms on the severity of peripheral artery disease in diabetic patients.

作者信息

Bleda Silvia, De Haro Joaquin, Varela Cesar, Esparza Leticia, De Maturana Ignacio Lopez, Acin Francisco

机构信息

Angiology and Vascular Surgery Department of Hospital Universitario de Getafe, Madrid, Spain.

出版信息

Growth Factors. 2012 Oct;30(5):277-82. doi: 10.3109/08977194.2012.703664. Epub 2012 Jul 5.

DOI:10.3109/08977194.2012.703664

PMID:22762535

Abstract

OBJECTIVE

To determine the potential genotype vascular endothelial growth factor (VEGF) gene differences in diabetic patients with peripheral arterial disease (PAD), which might be associated with different stages of the vascular disease.

METHODS

A study was conducted with type 2 diabetic patients with PAD [n = 70; 32 intermittent claudication and 38 critical limb ischaemia (CLI)]. Genotyping of the VEGF gene insertion/deletion - 2549, - 2578 C/A and +405 G/C polymorphisms was done in both groups and correlated them with the severity of PAD. We compared serum VEGF levels in both groups.

RESULTS

There was a higher frequency of +405 CC and - 2578 CC genotypes in claudication group [(31.3% vs. 5.4%, p = 0.01) and (37.5% vs. 15.8%, p = 0.05), respectively]. The presence of +405 GG and - 2578 AA genotypes was more common among CLI patients [(57.8% vs. 37.5%, p = 0.01) and (42.1% vs. 18.8%, p = 0.05), respectively]. There were higher serum VEGF levels in patients with CLI (p = 0.029).

CONCLUSIONS

We found preliminary evidence regarding the association between VEGF polymorphisms and different stages of PAD in diabetic patients.

摘要

目的

确定糖尿病伴外周动脉疾病（PAD）患者血管内皮生长因子（VEGF）基因的潜在基因型差异，这些差异可能与血管疾病的不同阶段相关。

方法

对2型糖尿病伴PAD患者进行研究（n = 70；32例间歇性跛行和38例严重肢体缺血（CLI））。对两组患者进行VEGF基因插入/缺失-2549、-2578 C/A和+405 G/C多态性基因分型，并将其与PAD的严重程度相关联。我们比较了两组患者的血清VEGF水平。

结果

跛行组中+405 CC和-2578 CC基因型的频率较高[分别为（31.3%对5.4%，p = 0.01）和（37.5%对15.8%，p = 0.05）]。+405 GG和-2578 AA基因型在CLI患者中更为常见[分别为（57.8%对37.5%，p = 0.01）和（42.1%对18.8%，p = 0.05）]。CLI患者的血清VEGF水平较高（p = 0.029）。